Total number of patients with reported Stevens-Johnson syndrome 1706
Drug class/name
Anti-infectives, n (%)
735 (43.1)
Beta-lactams, n (%) 348 (20.4)
Sulphonamides, n (%) 81 (4.7)
Tetracyclines, n (%) 70 (4.1)
Quinolones, n (%) 64 (3.8)
Macrolides, n (%) 50 (2.9)
Anti-mycobacterials, n (%) 31 (1.8)
Anti-protozoals, n (%) 22 (1.3)
Aminoglycosides, n (%) 21 (1.2)
Anti-virals, n (%) 14 (0.8)
Glycopeptides, n (%) 12 (0.7)
Anti-fungals, n (%) 8 (0.5)
Lincosamides, n (%) 7 (0.4)
Other anti-infectives, n (%) 7 (0.4)
Nervous System, n (%)
390 (22.9)
Musculoskeletal System, n (%)
348 (20.4)
Cardiovascular system, n (%)
55 (3.2)
Gastrointestinal System, n (%)
39 (2.3)
Respiratory System, n (%)
33 (1.9)
Anaesthesia, n (%)
24 (1.4)
Immune System and Malignant Diseases, n (%)
16 (0.9)
Ear, Nose and Throat, n (%)
8 (0.5)
Eye, n (%)
7 (0.4)
Skin, n (%)
5 (0.3)
Blood and Nutrition, n (%)
5 (0.3)
Genito-urinary system, n (%)
4 (0.2)
Vaccines, n (%)
2 (0.1)
Endocrine System, n (%)
2 (0.1)
Unknown Aetiology, n (%)
33 (1.9)